Edit Symbol List
Enter up to 25 symbols separated by commas or spaces in the text box below. These symbols will be available during your session for use on applicable pages.
Don't know the stock symbol? Use the
Symbol Lookup tool.
Alphabetize the sort order of my symbols
Investing just got easier…
Sign up now to become a NASDAQ.com member and begin receiving instant notifications when key events occur that affect the stocks you follow.Access Now
Key Stock Data
The current last sale of $113.96 is 230.03% Higher than the 52 week low.
|Intraday||Last 52 Weeks|
|High:||$ 114||$ 114.20|
|Low:||$ 113.68||$ 34.53|
ETFs with ONCE as a Top 10 Holding*
|Weighting||ETF Name (Symbol)||100-Day Price Change (%)|
|3.1%||SPDR Series Trust SPDR S&P Biotech ETF (XBI)||+3.73 (4.26%)|
|1.38%||Invesco Raymond James SB-1 Equity ETF (RYJ)||-1.60 (-3.53%)|
|0.47%||Inspire Small/Mid Cap Impact ETF (ISMD)||-0.85 (-3.13%)|
|*Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change. **Green highlights the top performing ETF by % change in the past 100 days.|
Company Description (as filed with the SEC)
On February 22, 2019, we entered into a definitive merger agreement to be acquired by Roche Holdings, Inc., or Roche. Pursuant to the merger agreement, and upon the terms and subject to the conditions thereof, a wholly owned acquisition subsidiary of Roche, or Merger Sub, will commence a cash tender offer, or the tender offer, to acquire all of the issued and outstanding shares of our common stock at a price per share of $114.50, net to the seller of such shares in cash, without interest, subject to any withholding of taxes required by applicable law. The completion of the tender offer will be conditioned on at least a majority of the shares of our outstanding common stock having been validly tendered into and not withdrawn from the offer, receipt of certain regulatory approvals, and other customary conditions. Following the completion of the tender offer, Merger Sub will merge with and into our company, with our company surviving as a wholly owned subsidiary of Roche. ... More ...
Nasdaq Official Price
Mar. 18, 2019
Mar. 18, 2019